📊 Peptide Side-Effect Explorer
Pick a symptom to see every published Phase 2/3 trial that reports it — sorted by frequency, with dose, population, and source citations.
1. Pick a symptom
Chips are sorted by the highest reported frequency across any trial — the ones at the top show up most often.
Pick a symptom chip above to see trial-level data.
Each result shows the exact Phase 2/3 trial, dose arm, patient population, and reported frequency — not blog-level claims.
About the data. Frequencies are drawn from published Phase 2/3 trial reports — primarily GLP-1 class (semaglutide, tirzepatide, retatrutide) where head-to-head placebo-controlled data is available. Absence of a symptom here means it was not a prespecified adverse event in that trial, not that it never occurs. Rare and long-tail events are under-represented.
v1 coverage:
9 distinct symptoms across 3 peptides and 7 landmark trials. Non-GLP-1 compounds (BPC-157, TB-500, GHK-Cu, etc.) are not yet included — their side-effect data comes mostly from case reports and preclinical work rather than randomised trials.
If you have a specific trial you'd like us to code, let us know.